Intermountain’s Precision Genomics Lab Begins Testing to Identify Hereditary Cancer Syndromes | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

Intermountain’s Precision Genomics Lab Begins Testing to Identify Hereditary Cancer Syndromes

February 5, 2018
by Rajiv Leventhal
| Reprints

Intermountain Healthcare has announced that its Precision Genomics Core Laboratory has begun to validate and launch several tests that will identify disease-causing genetic variants associated with hereditary cancer syndromes.

The Utah-based health system said that the development of hereditary cancer gene panels to be offered through the Intermountain Precision Genomics Core Laboratory, located in St. George, Utah. Intermountain Precision Genomics will soon move into the new stand-alone Intermountain Cancer Center of St. George, which is slated for completion this fall, officials said.

Intermountain officials noted a recent article in the Journal of Clinical Oncology (JOC), which revealed that there is an unmet need for genetic testing in women with a history of breast and ovarian cancer. The conclusion of the article “National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer” stated, “Fewer than one in five individuals with a history of breast cancer or ovarian cancer meeting specific National Comprehensive Cancer Network (NCCN) criteria have undergone genetic testing. Most have never discussed testing with a healthcare provider. Large national efforts are warranted to address this unmet need.”

Amber Guidry, Ph.D., Intermountain precision genomics scientist, has been working on validations for clinical genomics tests that will detect the presence of mutations in genes that are passed on from one generation to the next. Guidry stated, “The article in the JOC clearly provides data illustrating the need for increased awareness of hereditary cancer risk and lifesaving screenings to help reduce the risk of developing cancer.”

Much of the effort to identify, educate and test at-risk individuals is led by Intermountain Healthcare’s Cancer Genetic Counseling Service. According to Brent Hafen, who directs cancer genetic counseling for Intermountain, “Genetic testing may be used to identify individuals previously diagnosed with cancer as well as healthy individuals who have hereditary cancer gene mutations. Genetic counseling in association with genetic testing allows individuals with an increased cancer risk to obtain more frequent screenings at younger ages leading to earlier detection and treatment of many cancers.”

2018 Denver Health IT Summit

Renowned leaders in U.S. and North American healthcare gather throughout the year to present important information and share insights at the Healthcare Informatics Health IT Summits.

July 12 - 13, 2018 | Denver

Topics

News

VA Chief Information Officer Scott Blackburn Resigns

The Department of Veterans Affairs’ (VA) acting chief information officer (CIO), Scott Blackburn, has resigned from his position, effective immediately.

HIT Advisory Committee Advances Recommendations on Core Data for Interoperability

The Health Information Technology Advisory Committee, a federal advisory committee to the Office of the National Coordinator for Health IT (ONC), voted Wednesday to approve nine recommendations to update the list of data elements that vendors must exchange to be considered interoperable.

ACP Study: Only 37 Percent of MIPS Measures Are Valid

A new study from the American College of Physicians Performance Measurement Committee rated as valid only 37 percent of the 86 Quality Payment Program measures for 2017 deemed relevant to ambulatory general internal medicine.

Intermountain Healthcare Launches Study to Unlock Genomic Data

Researchers from the Salt Lake City, Utah-based Intermountain Healthcare have announced a long-term prospective study that they think has the potential to help physicians and others unlock genomic data.

UNC Health Care Receives HIMSS Analytics Stage 7 Designation

UNC Health Care, an integrated health care system based in Chapel Hill, N.C., has achieved Stage 7 designation on the HIMSS Analytics’ Electronic Medical Record Adoption Model (EMRAM).

FDA Announces Plan to Advance Medical Device Safety and Cybersecurity

The Food and Drug Administration (FDA) has announced new proposals aimed at advancing medical device cybersecurity, including placing new responsibilities on manufacturers, both before and after their devices hit the market.